Repligen Corporation $RGEN Stock Holdings Increased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its position in Repligen Corporation (NASDAQ:RGEN) by 154.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 130,277 shares of the biotechnology company’s stock after acquiring an additional 79,039 shares during the period. Daiwa Securities Group Inc. owned about 0.23% of Repligen worth $21,347,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Bayforest Capital Ltd purchased a new position in shares of Repligen in the fourth quarter worth approximately $32,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen in the fourth quarter worth approximately $33,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen in the third quarter worth approximately $29,000. Farther Finance Advisors LLC increased its position in shares of Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares in the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in shares of Repligen in the third quarter worth approximately $65,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of RGEN opened at $122.31 on Friday. The company’s 50 day moving average price is $118.67 and its 200 day moving average price is $138.77. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a market capitalization of $6.90 billion, a PE ratio of 135.90, a PEG ratio of 2.44 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.26 million for the quarter, compared to the consensus estimate of $192.05 million. During the same period in the previous year, the firm posted $0.39 earnings per share. The firm’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Research analysts expect that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price on the stock. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. HC Wainwright lifted their target price on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. UBS Group dropped their target price on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Finally, Barclays boosted their price objective on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.